While the reduction in price target from $12 to $8 by Wedbush could be seen as a negative signal, the maintenance of an Outperform rating suggests that the analyst still sees positive potential in Sutro Biopharma's stock in the short term. The mixed signals could lead to neutral market reaction in the short term as investors weigh the lowered price target against the continued positive outlook.